{
  "docId": "019de071-473e-712d-87f0-b99471a2308d",
  "docSlug": "b8bc6e04b9c70160cc1bc532a2ac4eea",
  "documentTitle": "Nuvalent | IPO Presentation Deck | 40 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7827299,
  "pageNumber": 23,
  "pageCount": 40,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "The slide uses a hybrid layout combining a staircase diagram for Phase 1 and a structured table for Phase 2.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-473e-712d-87f0-b99471a2308d/23",
  "deckHref": "/decks/019de071-473e-712d-87f0-b99471a2308d",
  "deckJsonHref": "/decks/019de071-473e-712d-87f0-b99471a2308d.json",
  "deckAnchorHref": "/decks/019de071-473e-712d-87f0-b99471a2308d#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.28,
        "x": 0.07,
        "y": 0.26
      },
      "kind": "diagram",
      "text": "Phase 1 dose escalation staircase from Dose Level 1 to 6.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb7b8dc1-42cb-42b3-9e73-0f5d9aa12183",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "*Either crizotinib or entrectinib; ** Platinum-based chemotherapy ± immunotherapy; *** Includes NSCLC who do not qualify for any of the other cohorts. I-O: Immunotherapy; RP2D: Recommended Phase 2 Dose; TKI: Tyrosine Kinase Inhibitor",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3866528-1c50-4509-870f-ddee7306747a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.6,
        "x": 0.35,
        "y": 0.26
      },
      "kind": "table",
      "text": "Phase 2 cohort details including tumor type, prior TKI, prior chemo/I-O, and specific subset analysis notes.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5cc5f5c-c617-4ad8-b5c8-e943bb743b2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "title",
      "text": "Phase 2 Cohorts Designed to Support Potential Registration in Kinase Inhibitor Naive or Previously Treated ROS1-positive NSCLC",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d77296ce-ddf6-4136-aa43-e710ec1b5ad3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.07,
        "y": 0.05
      },
      "kind": "title",
      "text": "Planned first-in-human clinical trial of NVL-520 in ROS1-positive NSCLC and other advanced solid tumors (ARROS-1)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6bce6f87-05d3-4134-bbb5-6a42868087d0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "2ecf57f5-dc73-46b4-a3fa-94740bcb9957",
      "evidence": "Structured cohort breakdown for regulatory registration",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 23,
      "from": 22,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "eb06e03e-4835-4d57-9906-4c725d518b80",
      "evidence": "The document presents the planned clinical trial as a significant milestone.",
      "position": 1,
      "objective": "Present the planned NVL-520 first-in-human clinical trial",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}